Chemomab Therapeutics (STU:2QV) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2QV Chemomab Therapeutics Ltd STU:2QV
34 GF Score
Price €2.98
View Full Analysis

What is Chemomab Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

STU:2QV
34GF Score
Chemomab Therapeutics Ltd STU:2QV
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chemomab Therapeutics Business Description

Other Exchanges CMMB:USA
Address 10 Habarzel Street, 10th Floor, Building C, Tel Aviv, ISR, 6158101
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
34GF Score

Get the complete analysis for STU:2QV

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.98
Price